NantHealth explores the impact of new biosimilar drugs for autoimmune treatment. We will discuss how payers can prepare for the...
Value-Based Healthcare and Evidence-Based Treatment Rank Highest Recently, we conducted a new survey on our LinkedIn asking respondents the question,...
The burden of cancer and autoimmune diseases is heavy on patients, providers, and payers in the United States. Nearly 40...
Proven in oncology, the Eviti Connect payer solution expands to help reduce reimbursement inefficiencies and manage drug costs for disease...
Providers don’t want to delay patient care. Payers don’t want to waste money on unwarranted, ineffective autoimmune care. Both want...
Cancer care is costly and complex; and if you don’t have the tools needed to effectively manage your cancer spend,...